Clinical trials: Kidney Disorder
Metastatic Renal Cell Cancer
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Axitinib is a drug which is approved by the FDA for patients with advanced kidney cancer who have already received some treatment. It works by reducing blood flow to a tumor.
- Trial name
- NCT02579811
- Testing
- Axitinib
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Case Comprehensive Cancer Center
End Stage Renal Disease
Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A
The primary purpose of this study is to test the feasibility of trials which change the dialysate (dialysis bath prescription) of potassium and bicarbonate according to a standardized algorithm and according to the results of…
- Trial name
- RADAR-A (NCT03519347)
- Testing
- Potassium Removal Maximization, Potassium Gradient Minimization, Alkalosis Avoidance
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- NYU Langone Health
Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back.
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma
- Trial name
- NCT00749892
- Testing
- Erlotinib Hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Renal Cell
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell…
- Trial name
- NCT00244764
- Testing
- GW786034
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Acute Lung Injury, Sepsis
Extracardiac Complications After Cardiac Surgery
Hypothesis of the study is that patients undergoing major cardiac surgery can develop extracardiac complications correlated to cardiopulmonary by pass.
- Conditions
- Acute Lung Injury, Sepsis, Infections, Acute Kidney Injury
- Trial name
- NCT01187004
- Where
- Italy
- Volunteers
- 164 people
- Sponsor
- University of Turin, Italy
Calcium Oxalate Urolithiasis
Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion
The purpose of this research study is to assess the efficacy of ingesting a small amount of the harmless bacterium Oxalobacter formigenes in establishing residence in the guts of healthy participants and to determine whether this…
- Trial name
- NCT03752684
- Testing
- Moderately high oxalate/low calcium diet non-colonized, Oxalobacter formigenes, Moderately high oxalate/low calcium diet colonized
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Chronic Hemodialysis (ESRD)
Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD
This study is a pilot study designed to compare the safety and cardiovascular effects of 26 weeks of combination hydralazine/isorsorbide dinitrate therapy with placebo therapy in patients receiving chronic hemodialysis.
- Trial name
- HIDE (NCT02228408)
- Testing
- Hydralazine/Isorsorbide Dinitrate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Brigham and Women's Hospital
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH)…
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT02282813
- Testing
- CTAP101 Capsules, Calcitriol, Doxercalciferol
- Volunteers
- 298 people
- Sponsor
- OPKO Health, Inc.
Lupus Nephritis
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
The purpose of this open-label extension study was to provide treatment with secukinumab for subjects who completed core study treatment in Study CAIN457Q12301 (NCT04181762), and to obtain further data on long-term efficacy…
- Trial name
- NCT05232864
- Testing
- Secukinumab
- Where
- 18 sites in Australia, Brazil and 11 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
End-Stage Renal Disease
L-Carnitine in Peritoneal Dialysis
The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy.
- Trial name
- NCT00922701
- Testing
- L-carnitine
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- Iperboreal Pharma Srl
Chronic Kidney Diseases
Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis
This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in CKD treated with erythropoiesis-stimulating agents (ESAs) and not…
- Trial name
- NCT02238067
- Testing
- ESA, Satisfaction Survey Questionnaire
- Where
- 7 sites in Israel
- Volunteers
- 196 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2, End-Stage Kidney Disease
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control.
- Trial name
- NCT00509236
- Testing
- Sitagliptin, Glipizide
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Metastases
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)
- Trial name
- NCT03075072
- Testing
- Whole brain radiation, Stereotactic radiation (SRS)
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- Brigham and Women's Hospital
End-stage Renal Failure, Graft Rejection
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
The current anti-rejection drug regime for kidney transplant recipients in use at the West London Renal \& Transplant Centre (WLRaTC) consists of induction therapy with the very potent monoclonal antibody Campath 1-H…
- Trial name
- TAESR (NCT00807144)
- Testing
- Tacrolimus (Kidney transplant maintenance immunosuppression), Kidney transplant maintenance immunosuppression
- Where
- United Kingdom
- Volunteers
- 102 people
- Sponsor
- Imperial College Healthcare NHS Trust
Chronic Kidney Disease
Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters
Numerous catheter designs have been studied to increase efficacy and minimize complications of catheter hemodialysis. Major complications of catheters include thrombosis, central venous stenosis, infection, and dialysis…
- Trial name
- NCT02796300
- Testing
- Bioflo Dialysis Catheter, Palindrome Dialysis Catheter
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, Los Angeles
Renal Cell Carcinoma
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
The primary objective of the study is to determine whether participants exhibit a measurable immune response after multiple administrations of HSPPC-96 (heat shock protein-peptide complex 96), as assessed by enzyme linked…
- Trial name
- NCT01147536
- Testing
- HSPPC-96
- Where
- 3 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Agenus Inc.
Renal Failure
Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
- Trial name
- NCT01666951
- Testing
- LCP-Tacro tablets, Prograf
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Veloxis Pharmaceuticals
Chronic Renal Insufficiency, Type 2 Diabetes Mellitus
A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)
This is a 2-part study in participants with renal impairment and matched healthy participants to investigate the effect of impaired renal function on the plasma and urine levels of omarigliptin (MK-3102) after taking a single 3…
- Trial name
- NCT01407276
- Testing
- Omarigliptin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postoperative Pain Management, Urolithiasis
The Use of Intranasal Ketoralac for Pain Management (Sprix)
Despite an overall reduction in the perioperative complication rate, post operative pain management after ureteroscopic removal of stones (URS) remains a major factor delaying discharge of patients.
- Trial name
- NCT01736358
- Testing
- Intranasal Ketoralac
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Montefiore Medical Center
Renal Insufficiency, Healthy
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.
- Trial name
- NCT03302091
- Testing
- BI 1467335
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.